FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology and immunology. Invention discloses isolated polynucleotides coding variable regions of light and heavy chains of antibody to human EGFR; anti-EGFR antibody and antibody fragment; as well as vector, host cell and method of producing anti-EGFR antibody or its fragment. There are disclosed: composition containing anti-EGFR antibody or its fragment, use thereof, as well as use of antibody and its fragment for treating disorders characterized by EGFR overexpression. Besides, method of detecting presence of EGFR in sample using disclosed antibodies is described.
EFFECT: present invention can find further application in treating EGFR-mediated diseases.
70 cl, 29 dwg, 38 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING MOLECULES, WHICH BIND EGFR, THEIR CODING VECTORS AND THEIR USAGE | 2006 |
|
RU2488597C2 |
| ANTIGEN-BINDING MOLECULES WHICH BIND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), VECTORS CODING THEM AND USING THEM | 2007 |
|
RU2457219C2 |
| AFFINITY-MATURED HUMANISED ANTI-CEA MONOCLONAL ANTIBODIES | 2010 |
|
RU2570554C2 |
| MODIFIED ANTIGEN-BINDING MOLECULES WITH CHANGED CELL SIGNAL ACTIVITY | 2006 |
|
RU2547931C2 |
| POLYSPECIFIC ANTIBODIES CONTAINING ANTIBODY OF FULL LENGTH AND ONE-CHAIN FRAGMENTS FAB | 2010 |
|
RU2598248C2 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
